Let’s be perfectly clear: in no case would the pharmaceutical company be taking a loss.
I’m not so sure about that.
In 2017, GSK announced it was looking to sell off Strimvelis,[13] and in March 2018, GSK sold Strimvelis to Orchard Therapeutics Ltd.; as of that time there had been only five sales of the product.[14]